Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19

• Status: Recruiting
• Trial end date: 2020-10-31
• Target enrollment: 0
• Participant gender: All

Summary

Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested.

In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

Participants eligible for inclusion will include non-pregnant adult (>18 years old) with molecular confirmation of COVID-19. [Participants will be eligible in a period of no longer than 72 hours after exposure].

Exclusion Criteria:

• Severe infection ( defined as need for invasive or non-invasive ventilator support, ECMO or shock requiring vasopressor support).

• Weight below 40Kg or above 100Kg

• Unable to take oral medication

• Known allergy to the drugs

• Pregnancy or breast feeding

• Participating in another RCT for treatment of COVID-19.